Inventor · disambiguated record
Takeru Yamakawa
Also filed as: YAMAKAWA TAKERU
11 granted patents·2 pending applications·44 citations·filing 2000–2019
84Inventor score
Files withMEIJI SEIKA PHARMA CO LTD4BANYU PHARMA CO LTD2IINO TOMOHARU2MERCK & CO INC2ISHIKAWA MAKOTO1
Top patents by PatentIndex Score
13 records- 0186US7410976B2Spirochromanone derivativesMERCK & CO INC·Filed 2006·Granted Aug 12, 2008·11 cites·29 claims
- 0281US6699880B1Substituted imidazolidinone derivativesBANYU PHARMA CO LTD·Filed 2000·Granted Mar 2, 2004·28 cites·16 claims
- 0374US10669283B2Compound and pharmacologically acceptable salt thereofMEIJI SEIKA PHARMA CO LTD·Filed 2017·Granted Jun 2, 2020·2 cites·6 claims
- 0472US8093389B2Substituted spirochromanone derivativesIINO TOMOHARU·Filed 2008·Granted Jan 10, 2012·2 cites·15 claims
- 0554US7279490B2Ophthalmic compositions for treating ocular hypertensionMERCK & CO INC·Filed 2003·Granted Oct 9, 2007·1 cites·15 claims
- 0651US7935712B2Spirochromanone derivatives as acetyl coenzyme A carboxylase (ACC) inhibitorsMERCK SHARP & DOHME·Filed 2006·Granted May 3, 2011·0 cites·2 claims
- 0746US12239643B2Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseasesMEIJI SEIKA PHARMA CO LTD·Filed 2019·Granted Mar 4, 2025·0 cites·7 claims
- 0845US8138197B2Spirochromanon derivativesIINO TOMOHARU·Filed 2008·Granted Mar 20, 2012·0 cites·3 claims
- 0944US2011065739A1Novel isoxazole drivativeISHIKAWA MAKOTO·Filed 2009·Application pending·0 cites
- 1043US8524730B2Spirochromanone carboxylic acidsJONA HIDEKI·Filed 2009·Granted Sep 3, 2013·0 cites·8 claims
- 1140US7164024B2Benzimidazolone derivativesBANYU PHARMA CO LTD·Filed 2002·Granted Jan 16, 2007·0 cites·12 claims
- 1238US9890142B2PDE4 inhibitorMEIJI SEIKA PHARMA CO LTD·Filed 2014·Granted Feb 13, 2018·0 cites·13 claims
- 1331US2019047966A1Novel compound and pharmacologically acceptable salt thereofMEIJI SEIKA PHARMA CO LTD·Filed 2017·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →